

Europäisches  
Patentamt

European Patent  
Office

PCT/EP 02/11062  
Office européen  
des brevets

*[Signature]*

10/528928

Rec'd PCT/PTO 23 MAR 2005

REC'D 17 OCT 2003  
WIPO PCT



### Bescheinigung

### Certificate

### Attestation

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten internationalen Patentanmeldung überein.

The attached documents are exact copies of the international patent application described on the following page, as originally filed.

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet international spécifiée à la page suivante.

Den Haag, den  
The Hague,  
La Haye, le

08. 10. 2003

## PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

Der Präsident des Europäischen Patentamts  
Im Auftrag  
For the President of the European Patent Office  
Le Président de l'Office européen des brevets  
p. o.

Mme. C. Rossi  
*[Signature]*

Patentanmeldung Nr. PCT/EP 02/11062  
Patent application no.  
Demande de brevet n°

Best Available Copy

**Blatt 2 der Bescheinigung**  
**Sheet 2 of the certificate**  
**Page 2 de l'attestation**



Anmeldung Nr.: PCT/EP 02/11062  
Application no.:  
Demande n°:

Anmelder: 1. Janssen Pharmaceutica N.V., - Beerse, Belgium  
Applicant(s): 2. MERCKEN, Marc - Beerse, Belgium (US only)  
Demandeur(s): 3. VANDERMEEREN, Marc - Beerse, Belgium (US only)

Bezeichnung der Erfindung:  
Title of the invention: Amyloid - Beta monoclonal antibodies, compositions, methods and uses  
Titre de l'invention:

Anmeldetag:  
Date of filing: 27 September 2002 (27.09.2002)  
Date de dépôt:

In Anspruch genommene Priorität(en)  
Priority(ies) claimed  
Priorité(s) revendiquée(s)

Staat:  
State:  
Pays:

Tag:  
Date:  
Date:

Aktenzeichen:  
File no.  
Numéro de dépôt:

Benennung von Vertragsstaaten : Siehe Formblatt PCT/RO/101 (beigefügt)  
Designation of contracting states : See Form PCT/RO/101 (enclosed)  
Désignation d'états contractants : Voir Formulaire PCT/RO/101 (ci-joint)

Bemerkungen:  
Remarks:  
Remarques:

## PCT REQUEST

PRD0032

Original (for SUBMISSION) - printed on 27.09.2002 02:21:31 PM

<b>III-2</b>	<b>Applicant and/or inventor</b>		
<b>III-2-1</b>	This person is:	<b>applicant and inventor</b>	
<b>III-2-2</b>	Applicant for	<b>US only</b>	
<b>III-2-4</b>	Name (LAST, First)	<b>VANDERMEEREN, Marc</b>	
<b>III-2-5</b>	Address:	<b>Turnhoutseweg 30 B-2340 Beerse Belgium</b>	
<b>III-2-6</b>	State of nationality	<b>BE</b>	
<b>III-2-7</b>	State of residence	<b>BE</b>	
<b>IV-1</b>	<b>Agent or common representative; or address for correspondence</b> The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as:	<b>common representative</b>	
<b>IV-1-1</b>	Name	<b>JANSSEN PHARMACEUTICA N.V.</b>	
<b>IV-1-2</b>	Address:	<b>Turnhoutseweg 30 B-2340 Beerse Belgium</b>	
<b>IV-1-3</b>	Telephone No.	<b>32+14 60 21 86</b>	
<b>IV-1-4</b>	Facsimile No.	<b>32+14 60 54 91</b>	
<b>IV-1-5</b>	e-mail	<b>patents@janbe.jnj.com</b>	
<b>V</b>	<b>Designation of States</b>		
<b>V-1</b>	Regional Patent (other kinds of protection or treatment, if any, are specified between parentheses after the designation(s) concerned)	<b>EP: AT BE BG CH LI CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR and any other State which is a Contracting State of the European Patent Convention and of the PCT</b>	
<b>V-2</b>	National Patent (other kinds of protection or treatment, if any, are specified between parentheses after the designation(s) concerned)	<b>US</b>	
<b>VI</b>	<b>Priority claim</b>	<b>NONE</b>	
<b>VII-1</b>	<b>International Searching Authority Chosen</b>	<b>European Patent Office (EPO) (ISA/EP)</b>	
<b>VIII</b>	<b>Declarations</b>	<b>Number of declarations</b>	
<b>VIII-1</b>	Declaration as to the identity of the inventor	-	
<b>VIII-2</b>	Declaration as to the applicant's entitlement, as at the International filing date, to apply for and be granted a patent	-	
<b>VIII-3</b>	Declaration as to the applicant's entitlement, as at the International filing date, to claim the priority of the earlier application	-	
<b>VIII-4</b>	Declaration of inventorship (only for the purposes of the designation of the United States of America)	-	
<b>VIII-5</b>	Declaration as to non-prejudicial disclosures or exceptions to lack of novelty	-	

## AMYLOID-BETA MONOCLONAL ANTIBODIES, COMPOSITIONS, METHODS AND USES

This invention relates to antibodies, including specified portions or variants,  
5 specific for at least the human Amyloid-beta<sub>11</sub> N-terminal site, *i.e.* A $\beta$ <sub>11-x</sub>  
peptides. It further provides methods of making and using said antibodies,  
including therapeutic formulations, administration and devices.

### BACKGROUND OF THE INVENTION

10 The present invention relates generally to methods and compositions for  
monitoring the processing of  $\beta$ -amyloid precursor protein. More particularly, the  
present invention relates to the use of such methods and compositions for the diagnosis,  
prognosis and monitoring response to therapy of Alzheimer's disease and other beta-  
amyloid related diseases as well as to the use of the disclosed antibodies in passive  
15 immunization as a method for treatment of Alzheimer's disease and other beta-amyloid  
related diseases.

Alzheimer's Disease (AD) is a degenerative brain disorder characterized clinically by  
progressive loss of memory, cognition, reasoning, judgment and emotional stability that  
gradually leads to profound mental deterioration and ultimately death. AD is a very  
20 common cause of progressive mental failure (dementia) in aged humans and is believed  
to represent the fourth most common medical cause of death in the United States. AD  
has been observed in races and ethnic groups worldwide and presents a major present  
and future public health problem. The disease is currently estimated to affect about two  
to three million individuals in the United States alone. AD is at present incurable. No  
25 treatment that effectively prevents AD or reverses its symptoms and course is currently  
known.

The brains of individuals with AD exhibit characteristic lesions termed senile (or  
amyloid) plaques, amyloid angiopathy (amyloid deposits in blood vessels) and  
neurofibrillary tangles. Large numbers of these lesions, particularly amyloid plaques  
30 and neurofibrillary tangles, are generally found in several areas of the human brain  
important for memory and cognitive function in patients with AD. Smaller numbers of  
these lesions in a more restricted anatomical distribution are also found in the brains of  
most aged humans who do not have clinical AD. Amyloid plaques and amyloid  
angiopathy also characterize the brains of individuals with Trisomy 21 (Down's

Syndrome), Diffuse Lewy Body Disease and Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type (HCHWA-D).

A major constituent of amyloid plaques are a variety amyloid-beta (A $\beta$ ) peptides which are produced by cleavage of the  $\beta$ -amyloid precursor protein (APP).  
5 While in the past there was significant scientific debate over whether the plaques and tangles are a cause or are merely the result of Alzheimer's disease, recent discoveries indicate that amyloid plaque is a causative precursor or factor. In particular, it has been discovered that the production of A $\beta$  peptides can result from mutations in the gene encoding amyloid precursor protein, a protein which when normally processed will not  
10 produce the A $\beta$  peptides. The identification of mutations in the amyloid precursor protein gene which cause familial, early onset Alzheimer's disease is the strongest evidence that amyloid metabolism is the central event in the pathogenic process underlying the disease. It is presently believed that a normal (non-pathogenic) processing of the APP protein occurs via cleavage by an "alpha.-secretase" which  
15 cleaves between amino acids 16 and 17 of the A $\beta$  peptide region within the protein. It is further believed that pathogenic processing occurs in part via "beta.- secretases" which cleave at the amino-terminus of the A $\beta$  peptide region within the precursor protein.

Recently, it was demonstrated that BACE-1 is the major  $\beta$ -secretase required for cleavage of APP at position +1 and that overexpression of BACE-1 results in an  
20 additional cleavage at the +11 site of the A $\beta$ , generating shorter A $\beta$ <sub>11-40</sub> and A $\beta$ <sub>11-42</sub> fragments, hereinafter also referred to as the A $\beta$ <sub>11-x</sub> peptides. These A $\beta$  peptides have been detected in conditioned medium of primary rat neuronal cell cultures and mouse N2a cells, suggesting that they are normal APP cleavage products generated in neurons (3, 4, 5). Significantly, these shorter A $\beta$  fragments have also been identified as major  
25 species in AD brains and normal aging brains by biochemical analysis (6) as well as in Down syndrome brains with AD pathology by immunohistochemistry studies (7). This event calls for a re-evaluation of the role of A $\beta$ <sub>11-40/42</sub> in the pathogenesis of Alzheimer's disease, especially in view of the fact that A $\beta$  species beginning at Glu11 prove to be more insoluble than those beginning at position 1 of A $\beta$ .

30 Despite the progress which has been made in understanding the underlying mechanisms of AD and other A $\beta$  -related diseases, there remains a need to develop methods and compositions for diagnosis and treatment of the disease(s). Thus, the ability to monitor cellular processing of the amyloid precursor protein would be of significant value in the diagnosis, prognosis, and therapeutic supervision of Alzheimer's  
35 disease. In particular, it would be desirable to identify minimally invasive procedures for screening and evaluating detectable diagnostic markers in readily obtainable patient samples, such as serum, cerebrospinal fluid (CSF), and the like.

A number of potential diagnostic markers for Alzheimer's disease have been proposed. Of particular interest to the present invention are the shorter carboxy-terminal fragments of the A $\beta$  precursor protein obtained after beta-secretase cleavage of the APP protein. These markers should be useful by themselves and/or in combination with  
5 other diagnostic markers and procedures. Preferably, the diagnostic markers would be detectable in body fluids, such as CSF, blood, plasma, serum, urine, tissue, and the like, so that minimally invasive diagnostic procedures can be utilized.

Specific assays for A $\beta$ 11-x detection should be capable of detecting A $\beta$ 11-x in fluid samples at very low concentrations as well as distinguishing between A $\beta$ 11-x  
10 peptides and other fragments of APP which may be present in the sample.

These and other aspects of the invention are described herein in more detail.

#### SUMMARY OF THE INVENTION

15 The present invention provides monoclonal antibodies which specifically recognize the shorter A $\beta$  peptides obtained after cleavage of the APP protein by BACE-1 at G11, i.e. the A $\beta$ -peptide fragments A $\beta$ 11-40 and A $\beta$ 11-42, hereinafter also referred to as the A $\beta$ 11-x peptides. It further provides hybridoma cells producing the monoclonal antibodies as well as methods for producing the  
20 antibodies and the hybridoma cells; and an immunoassay for an A $\beta$  peptide by a competitive method or a sandwich method using the antibody.

In particular, the present invention provides monoclonal antibodies prepared using the first 5 to 7 human amino acids of the  $\beta$ -secretase<sub>11</sub> cleavage site, i.e. EVHHQ-C (human A $\beta$ <sub>11</sub>(6 AA) - Seq Id No.:1) and EVHHQKL-C  
25 (human A $\beta$ <sub>11</sub>(8 AA) - Seq Id No.:2) or using the first 5 to 7 mouse amino acids of the  $\beta$ -secretase<sub>11</sub> cleavage site, i.e. EVRHQ-C (mouse A $\beta$ <sub>11</sub>(6 AA) - Seq Id No.:3) and EVRHQKL-C (mouse A $\beta$ <sub>11</sub>(8 AA) - Seq Id No.:4) as immunogens. Said antibodies specifically react with the A $\beta$ 11-x peptides without cross reactivity for other APP fragments and accordingly, are useful in an immunoassay to assess  
30 the role of A $\beta$ 11-x in the pathogenesis of Alzheimer's disease.

In a more specific embodiment the monoclonal antibodies are reactive to the human A $\beta$ <sub>11</sub>(6 AA) immunogen and expressed by the hybridoma cells J&JPRD/hA $\beta$ 11/1 and J&JPRD/hA $\beta$ 11/2 deposited at the Belgian coordinated collection of microorganisms on August 19, 2002 with accession numbers LMBP  
35 5896CB and LMBP 5897CB respectively. It is thus a further embodiment of the present invention to provide the aforementioned hybridoma cells expressing the monoclonal antibodies according to the invention.

In a further aspect of the present invention the antibodies according to the invention are used in conventional immunological techniques for the detection of A $\beta$ <sub>11-x</sub> peptides wherever it may occur, including biological samples for the monitoring of  $\beta$ -amyloid-related diseases and conditioned media from cell culture  
5 for monitoring the intracellular processing of APP. Suitable immunological techniques are well known to those skilled in the art and include for example, ELISA, Western Blot analysis, competitive or sandwich immunoassays and the like, as is otherwise well known they all depend on the formation of an antigen-antibody immune complex wherein for the purpose of the assay, the antibody can be  
10 detectable labeled with, e.g. radio, enzyme or fluorescent labels or it can be immobilized on insoluble carriers.

The invention also includes the use of a humanized antibody of the invention for the manufacture of a medicament, for treating, preventing or reversing Alzheimer's disease, Down's syndrome, HCHWA-D, cerebral amyloid angiopathy  
15 or other  $\beta$ -amyloid-related diseases; for treating, preventing or reversing cognitive decline in clinical or pre-clinical Alzheimer's disease, Down's syndrome, HCHWA-D or cerebral amyloid angiopathy; or to inhibit the formation of amyloid plaques or the effects of toxic soluble A $\beta$  species in humans.

## 20 BRIEF DESCRIPTION OF THE DRAWING

Figure 1 A : Serum titrations of mice injected with the first 5 to 7 human amino acids of the  $\beta$ -secretase<sub>11</sub> cleavage site, i.e. EVHHQ-C (human A $\beta$ <sub>11</sub>(5 AA) – Seq Id No.:1) and EVHHQKI-C (human A $\beta$ <sub>11</sub>(7 AA) – Seq Id No.:2) or with the first 5 to 7 mouse amino acids of the  $\beta$ -secretase<sub>11</sub> cleavage site, i.e. EVRHQ-C (mouse A $\beta$ <sub>11</sub>(5 AA) – Seq Id  
25 No.:3) and EVRHQKL-C (mouse A $\beta$ <sub>11</sub>(7 AA) – Seq Id No.:4) as immunogens. Coating antigen used was hA $\beta$ (11-40) (American Peptide Company) at 2.0  $\mu$ g/ml.

30 Table 1 Immunization procedure and time lines for spleen collection and fusion for mice injected with EVHHQ-C (human A $\beta$ <sub>11</sub>(5 AA) – Seq Id No.:1).

Fig 2 Sandwich ELISA using purified monoclonal antibodies JRF/A $\beta$ N/25, J&JPRD/hA $\beta$ 11/1 and J&JPRD/hA $\beta$ 11/2 as capturing antibodies and JRF/cA $\beta$ 40/10-HRPO as detecting antibody. Antibody combinations are evaluated for reactivity with human A $\beta$ 1-40 and human A $\beta$ 11-40 (American Peptide Company).

A: Combination JRF/A $\beta$ N/25 with JRF/cA $\beta$ 40/10-HRPO reacts specifically with human A $\beta$ 1-40 without cross reaction to hA $\beta$ 11-40 (positive control for A $\beta$ 1-40 detection).

B: Combination J&JPRD/hA $\beta$ 11/1 with JRF/cA $\beta$ 40/10-HRPO reacts specifically with hA $\beta$ 11-40 without crossreaction to human A $\beta$ 1-40.

C: Combination J&JPRD/hA $\beta$ 11/2 with JRF/cA $\beta$ 40/10-HRPO reacts specifically with hA $\beta$ 11-40 without crossreaction to human A $\beta$ 1-40.

Fig 3 Western blotting showing specific reaction of J&JPRD/hA $\beta$ 11/1 with  $\beta$ 11-cleaved CTF fragments of APP in membrane extracts of HEK cells stably transfected with human APP<sup>swe</sup> and Human BACE1. C6/6.1 is directed to the C-terminus of APP and reacts with both  $\beta$ 1- and  $\beta$ 11-cleaved CTF fragments of APP.

#### DETAILED DESCRIPTION

The present invention provides monoclonal antibodies which specifically recognize the shorter A $\beta$  peptides obtained after cleavage of the APP protein by BACE-1 at Glu11. The antibodies of the invention have specificity to one or more epitopes present on the first 5 to 7 amino acids of the  $\beta$ -secretase<sub>11</sub> cleavage site of human A $\beta$  or on the first 5 to 7 amino acids of the  $\beta$ -secretase<sub>11</sub> cleavage site of mouse A $\beta$ .

In particular, the present invention provides monoclonal antibodies prepared using peptides consisting of the first 5 to 7 human amino acids of the  $\beta$ -secretase<sub>11</sub> cleavage site, i.e. EVHHQ-C (human A $\beta$ <sub>11</sub>(6 AA) – Seq Id No.:1) and EVHHQKI-C (human A $\beta$ <sub>11</sub>(8 AA) – Seq Id No.:2) or using the first 5 to 7 mouse amino acids of the  $\beta$ -secretase<sub>11</sub> cleavage site, i.e. EVRHQ-C (mouse A $\beta$ <sub>11</sub>(6 AA) – Seq Id No.:3) and EVRHQKL-C (mouse A $\beta$ <sub>11</sub>(8 AA) – Seq Id No.:4) as immunogens.

The aforementioned peptides may be prepared produced by methods known in the art, such as the well-known Merrifield solid-phase synthesis technique where amino acids are sequentially added to a growing chain (Merrifield (1963) J.Am.Chem.Soc.



85:2149-2156) . The amino acids sequences may be based on the sequence of the A $\beta$  fragments set forth above or may utilize naturally occurring or engineered mutant sequences. For use as immunogen, the peptides thus obtained may be used by itself or may be conjugated to a suitable immunoactivating natural or synthetic carrier, such as maleimide activated serum albumin of mammals such as bovine, rabbit, and human, thyroglobulin of mammals such as bovine, rabbits, human and sheep and keyhole limpet hemocyanin (KLH) or other suitable protein carriers such as the synthetic polymer carriers including styrene polymers, acrylic polymers, vinyl polymers and propylene polymers. Further detailed descriptions of immunization can be found in the examples.

Once a sufficient amount of the immunogen has been obtained, polyclonal antibodies specific for the A $\beta$ 11-x peptides may be produced in various ways using techniques including in vitro or in vivo techniques. In vitro techniques involve exposure of lymphocytes to the immunogens, while in vivo techniques require the injection of the immunogens into a suitable vertebrate host. Suitable vertebrate hosts are non-human, including mice, rats, rabbits, sheep, goats and the like. Immunogens are injected into the animal according to a predetermined schedule, and the animals are periodically bled with successive bleeds having improved titer and specificity. The injections may be made intramuscularly, intraperitoneally, subcutaneously, or the like and an adjuvant, such as Freund's complete adjuvant or Freund's incomplete adjuvant may be given to enhance antibody producing ability. Methods for screening the serum titer levels typically include standard ELISA or RIA assays. For example in an ELISA screening format the serum is added to a solid phase (for example the bottom of a microplate) which is coated with either the A $\beta$ 11-x peptide or the A $\beta$ 11-x peptide coupled to a carrier (such as BSA), and then, adding an anti-immunoglobulin antibody (for example when the immunization is performed in mice, an anti-mouse immunoglobulin antibody is used, e.g. sheep-anti-mouse immunoglobulin (Ig)) conjugated with a detectable label such as an enzyme, preferably horseradish peroxidase, or a radioactive isotope such as <sup>125</sup>I.

If desired, monoclonal antibodies can be prepared from the vertebrate hosts, such as a mouse, hyperimmunized with the desired immunogen by the method just described, using techniques well understood by those having ordinary skill in the art. Conveniently, a vertebrate host showing a high titer antibody is selected from the animals immunized with the desired immunogen. Typically 2 to 5 days, preferably 4 days after the final immunization, the spleen or lymph nodes are collected therefrom, and antibody-producing cells contained therein immortalized. The manner of immortalization is not critical. Presently, the most common technique is fusion with a

myeloma cell fusion partner. The fusing procedure can be conducted according to methods known in the art, for example, the method of Kohler and Milstein (Nature, 256, 495-497 (1975)). Other techniques include EBV transformation, transformation with bare DNA e.g. oncogenes, retroviruses, etc., or any other method which provides  
5 for stable maintenance of the cell line and production of monoclonal antibodies. Fusion accelerators, including polyethylene glycol (PEG) and Sendai virus, may be used. In particular PEG is preferably used. Examples of the myeloma cells include NS-1, P3U1, SP2/0 and AP-1, SP2/0 cells are preferably used.

Hybridomas producing monoclonal antibodies specific for epitopes which are  
10 found on the first 5 to 7 amino acids of the  $\beta$ -secretase<sub>11</sub> cleavage site of human A $\beta$  or on the first 5 to 7 amino acids of the  $\beta$ -secretase<sub>11</sub> cleavage site of mouse A $\beta$  are most effectively produced by first immunizing an animal from which hybridomas can be produced such as, for example a Balb/c mouse, with initial intraperitoneally injections of the desired immunogens in Freund's adjuvant, followed by booster  
15 injections every two weeks. The subsequent fusion of the isolated spleen can be carried out using any techniques commonly known to those of ordinary skill in the art, preferably using SP2/0 cells by a modified procedure of Kohler and Milstein (Eur. J. Immunol., 6, 292-295 (1976)). The screening of the hybridomas to determine which ones are producing antibodies specific for the A $\beta$ <sub>11-x</sub> peptides can be done either in a  
20 standard ELISA or RIA assay as described hereinbefore. Selection and breeding of the hybridomas producing the desired monoclonal antibodies, is usually conducted in a medium for animals (for example Dulbecco's modified Eagle's medium (DMEM) or Eagle's minimum essential medium (MEM)) supplemented with 10-20% fetal calf serum and other components such as, for example, HAT (hypoxanthine, aminopterin and thymidine), or ESG Hybridoma supplement. Accordingly in one embodiment the  
25 present invention provides the hybridoma cells J&JPRD/hA $\beta$ <sub>11/1</sub> and J&JPRD/hA $\beta$ <sub>11/2</sub> deposited at the Belgian coordinated collection of microorganisms on August 19, 2002 with accessionnumbers LMBP 5896CB and LMBP 5897CB respectively.

30 Separation and purification of the anti- A $\beta$ <sub>11-x</sub> monoclonal antibodies are carried out similarly to usual separation and purification of polyclonal antibodies such as salt precipitation, alcohol precipitation, isoelectric precipitation, electrophoresis, adsorption and desorption with ion-exchange materials (for example DEAE), ultracentrifugation, gel filtration and specific immunoaffinity separation techniques  
35 including antigen-binding solid phases and protein A or protein G affinity chromatography. Suitable protein purification techniques are described in *Methods in*

*Enzymology*, Vol.182, Deutcher, ed., Academic Press. Inc., San Diego, 1990, the disclosure of which is incorporated herein by reference.

5 It is thus an object of the invention to provide isolated monoclonal antibodies expressed by the aforementioned hybridoma cells, said antibodies capable of specifically recognising A $\beta$ 11-x peptides. Preferably these isolated monoclonal antibodies are expressed by the hybridoma cells J&JPRD/hA $\beta$ 11/1 and J&JPRD/hA $\beta$ 11/2 deposited at the Belgian coordinated collection of microorganisms on August 19, 2002 with accessionnumbers LMBP 5896CB and LMPB 5897CB respectively.

10 The antibodies according to the invention are used in conventional immunological techniques for the detection of A $\beta$ 11-x peptides wherever it may occur, including biological samples for the monitoring of  $\beta$ -amyloid-related diseases and conditioned media from cell culture for monitoring the intracellular processing of APP. Suitable immunological techniques are well known to those skilled in the art and  
15 include for example, ELISA, Western Blot analysis, competitive or sandwich immunoassays and the like, as is otherwise well known they all depend on the formation of an antigen-antibody immune complex wherein for the purpose of the assay, the antibody can be detectable labeled with, e.g. radio, enzyme, luminescent or fluorescent labels or it can be immobilized on insoluble carriers. It is thus an object of  
20 the invention to provide immunoassays for the determination or detection of A $\beta$ 11-x peptides in a sample, the method comprising contacting the sample with an antibody to A $\beta$ 11-x peptides according to the invention and determining whether an immune complex is formed between the antibody and the A $\beta$ 11-x peptide. These methods can either be performed on tissue samples or body fluid samples and generally comprise  
25 obtaining a sample from the body of a subject; contacting said sample with an imaging effective amount of a detectably labeled antibody according to the invention; and detecting the label to establish the presence of A $\beta$ 11-x peptides in the sample.

The measuring methods using the antibodies of the present invention are not particularly limited. Any measuring method may be used as long as the amount of  
30 antibodies, antigens or the antigens-antibody complexes corresponding to the amount of the antigens, in particular the amount of A $\beta$ 11-x peptides in solutions to be measured is detected by chemical or physical means, and calculated from standard curves prepared by the use of standard solutions containing the antigens in known amounts. For example, nephelometry, competitive methods, immunometric methods and sandwich  
35 methods are suitably used. With respect to sensitivity and specificity, it is particularly preferred to use sandwich methods described below.

In measuring methods using labelling substances, radioisotopes, enzymes, fluorescent substances, luminous substances, etc. are used as labelling agents. Examples of the radioisotopes include  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^3\text{H}$  and  $^{14}\text{C}$ . Enzymes are usually made detectable by conjugation of an appropriate substrate that, in turn catalyzes a detectable reaction. Examples thereof include, for example, beta-galactosidase, beta-glucosidase, alkaline phosphatase, peroxidase and malate dehydrogenase, preferably horseradish peroxidase. The luminous substances include, for example, luminol, luminol derivatives, luciferin, aequorin and luciferase. Further, the avidin-biotin systems can also be used for labelling the antibodies and immunogens of the present invention.

When the immunogens or antibodies are insolubilized, either physical adsorption or chemical binding usually used for insolubilization or fixation of proteins or enzymes may be employed. Examples of the carriers include insoluble polysaccharides such as agarose, dextran, and cellulose, synthetic resins such as polystyrene, polyacrylamide and silicone polymers, and glass.

In the sandwich methods, the test solutions are reacted with the insolubilized anti-A $\beta$ 11-x peptide antibodies (the first reaction), further, the labeled anti-A $\beta$ 11-x peptide antibodies are reacted (the second reaction), and then, the activity of the labeling agents on the insolubilized carriers is assayed, whereby the amount of the A $\beta$ 11-x peptides in the test solutions can be determined. The first reaction and the second reaction may be conducted simultaneously or sequentially.

In a further embodiment for diagnosing  $\beta$ -amyloid-related diseases a biological sample including tissue, body fluids, such as CSF, blood, plasma, serum, urine, and the like, is contained and contacted with a suitable amount of first antibody to produce an immune complex. The contact typically involves adding the sample to a solid matrix coated with the first antibody. The complex which results from contacting the sample with the first antibody is separated from the sample by elution. However, other methods of recovery may be employed. The recovered complex is contacted with at least one second antibody directed to an antigenic determinant on the antigen and capable of binding the antigen in the complex. The antigenic determinant to which the second antibody is directed may be the same one as to which the first antibody is directed due to the multiepitopic nature of the antigenic entity. Either the first or the second antibody may be made detectable using any of the labels described above. In a preferred embodiment, the second antibody is made detectable. The presence of the detectable antibody bound to the complex consisting of antigen bound to the first and second antibody may be readily detected using art-known techniques. By comparing the results obtained in the biological sample with those obtained on a control sample, the presence of altered A $\beta$ 11-x peptide levels may be determined.

It is accordingly, an object of the present invention to provide a sandwich assay wherein the first antibody coated to a solid matrix, hereinafter referred to as the coating antibody, consists of an antibody that recognizes the A $\beta$ 11-x peptides and full length A $\beta$ 40 or A $\beta$ 42 and the second antibody, which is made detectable, specifically recognizes the A $\beta$ 11-x peptides. Preferably, the coating antibody recognizes the human A $\beta$ 11-x peptides and full length human A $\beta$ 40 or A $\beta$ 42, in a more preferred embodiment the coating antibody consists of the monoclonal antibody JRF/cA $\beta$ 40/10 that specifically recognizes A $\beta$ 11-40 and full length A $\beta$ 40, said monoclonal antibody being characterised by comprising at least one heavy chain variable region heaving the amino acid sequence of SEQ ID No:5 and /or at least one light chain variable region having the amino acid sequence of SEQ ID No:6 (hereinafter referred to as the monoclonal antibody JRF/cA $\beta$ 40/10) or alternatively, the coating antibody consists of the monoclonal antibody JRF/cA $\beta$ 42/12 that specifically recognizes A $\beta$ 11-42 and full length A $\beta$ 42, said monoclonal antibody being characterised by comprising at least one heavy chain variable region heaving the amino acid sequence of SEQ ID No:7 and /or at least one light chain variable region having the amino acid sequence of SEQ ID No:8 (hereinafter referred to as the monoclonal antibody JRF/cA $\beta$ 42/12). Accordingly in a preferred embodiment the second antibody is one of the monoclonal antibodies expressed by the hybridoma cells J&JPRD/hA $\beta$ 11/1 or J&JPRD/hA $\beta$ 11/2 deposited at the Belgian coordinated collection of microorganisms on August 19, 2002 with accessionnumbers LMBP 5896CB and LMBP 5897CB respectively. It is also an object of the invention to provide a sandwich assay to determine the ratio of A $\beta$ 11-x peptides to full length A $\beta$ 40 or A $\beta$ 42. In this embodiment an additional second antibody that recognizes both full length A $\beta$ 40 and A $\beta$ 42, but which shows no cross reactivity for A $\beta$ 11-x peptides is used as well. Preferably this additional second antibody consists of JRF/A $\beta$ N25 characterised by comprising at least one heavy chain variable region heaving the amino acid sequence of SEQ ID No: 9 and /or at least one light chain variable region having the amino acid sequence of SEQ ID No: 10.

In an alternative sandwich assay to determine the ratio of A $\beta$ 11-x peptides to full length A $\beta$ 40 or A $\beta$ 42, the coating antibody consists of an antibody that specifically recognizes the A $\beta$ 11-x peptides, preferably the human A $\beta$ 11-x peptides and the second antibody, which is made detectable, specifically recognizes the peptides A $\beta$ 11-40 or A $\beta$ 11-42, preferably human A $\beta$ 11-40 or human A $\beta$ 11-42. In this alternative sandwich assay the coating antibody consists of one of the monoclonal antibodies expressed by the hybridoma cells J&JPRD/hA $\beta$ 11/1 or J&JPRD/hA $\beta$ 11/2 deposited at the Belgian coordinated collection of microorganisms on August 19, 2002 with accessionnumbers LMBP 5896CB and LMBP 5897CB respectively, and the second, detectably labeled

antibody consist of either the monoclonal antibody JRF/cA $\beta$ 40/10 or the monoclonal antibody JRF/cA $\beta$ 42/12 as characterized hereinbefore.

5 The monoclonal antibodies of the present invention can also be used in assay systems other than the sandwich methods, for example, competitive methods and nephelometry. In the competitive methods, antigens in test solutions and labeled immunogens are competitively reacted with the antibodies, followed by separation of the unreacted labeled immunogens (F) from the labeled immunogens (B) bound to the antibodies (B/F separation). Then, the labeled amount of either B or F is measured to determine the amount of immunogen in the test solution. These reaction methods  
10 include liquid phase methods in which soluble antibodies are used as the antibodies and polyethylene glycol and the second antibodies to the above mentioned antibodies are used for B/F separation, and solidifying methods in which solidified antibodies are used as the first antibodies, or soluble antibodies are used as the first antibodies and solidified antibodies are used as the second antibodies.

15 In nephelometry, the amount of the insoluble precipitates produced as a result of antibody-antigen reaction in gels or solutions is measured. Even when the amount of antigens is slight, and the precipitates are obtained only in small amounts, laser nephelometry using laser scattering is suitably used.

In a further aspect, the invention is directed to a method to treat and to prevent conditions characterized by the formation of plaques containing beta- amyloid protein in humans, which method comprises administering, preferably peripherally, to a human in need of such treatment a therapeutically or prophylactically effective amount of humanized monoclonal antibody according to the invention or immunologically reactive fragment thereof, which antibody specifically binds to one or more epitopes  
20 present on the first 5 to 7 amino acids of the  $\beta$ -secretase<sub>11</sub> cleavage site of human or mouse A $\beta$  peptide. In another aspect, the invention is directed to a method to inhibit the formation of amyloid plaques and to clear amyloid plaques in humans, which method comprises administering to a human subject in need of such inhibition an effective amount of a humanized antibody that sequesters A $\beta$  peptide from its circulating form in  
25 blood and induces efflux out of the brain as well as altered A $\beta$  clearance in plasma and the brain. In additional aspects, the invention is directed to such humanized antibodies, including immunologically effective portions thereof, and to methods for their preparation.

By "humanized antibody" is meant an antibody that is composed partially or  
35 fully of amino acid sequences derived from a human antibody germline by altering the sequence of an antibody having non-human complementarity determining regions (CDR). "CDRs" are defined as the complementarity determining region amino acid

sequences of an antibody which are the hypervariable regions of immunoglobulin heavy and light chains. See, e.g. Kabat *et al.*, Sequences of proteins of immunological interest, 4<sup>th</sup> Ed., U.S. Department of Health and Human Services, National Institutes of Health (1987). There are three heavy chain and three light chain CDRs (or CDR regions) in the variable portion of an immunoglobulin. Thus "CDRs" as used herein refers to all three heavy chain CDRs or all three light chain CDRs (or both light and heavy chain CDRs, if appropriate).

The simplest such alteration may consist simply of substituting the constant region of a human antibody for the murine constant region, thus resulting in a human/murine chimera which may have sufficiently low immunogenicity to be acceptable for pharmaceutical use.

Preferably, however, the variable region of the antibody and even the CDR is also humanized by techniques that are by now well known in the art. The framework regions of the variable regions are substituted by the corresponding human framework regions leaving the non-human CDR substantially intact, or even replacing the CDR with sequences derived from a human genome. Fully human antibodies are produced in genetically modified mice whose immune systems have been altered to correspond to human immune systems. As mentioned above, it is sufficient for use in the methods of the invention, to employ an immunologically specific fragment of the antibody, including fragments representing single chain forms.

A humanized antibody again refers to an antibody comprising a human framework, at least one CDR from a non-human antibody, and in which any constant region present is substantially identical to a human immunoglobulin constant region, i.e., at least about 85-90%, preferably at least 95% identical. Hence, all parts of a humanized antibody, except possibly the CDRs, are substantially identical to corresponding parts of one or more native human immunoglobulin sequences. For example, a humanized immunoglobulin would typically not encompass a chimeric mouse variable region/human constant region antibody.

Humanized antibodies have at least three potential advantages over non-human and chimeric antibodies for use in human therapy:

1) because the effector portion is human, it may interact better with the other parts of the human immune system (e.g., destroy the target cells more efficiently by complement-dependent cytotoxicity (CDC) or antibody-dependent cellular cytotoxicity (ADCC)).

2) The human immune system should not recognize the framework or C region of the humanized antibody as foreign, and therefore the antibody response against such an

injected antibody should be less than against a totally foreign non- human antibody or a partially foreign chimeric antibody.

- 3) Injected non-human antibodies have been reported to have a half-life in the human circulation much shorter than the half-life of human antibodies. Injected humanized antibodies will have a half-life essentially identical to naturally occurring human antibodies, allowing smaller and less frequent doses to be given.

- In a method to treat and to prevent conditions characterized by the formation of plaques containing beta- amyloid protein, the antibodies (including immunologically reactive fragments) are administered to a subject at risk for or exhibiting A $\beta$ -related symptoms or pathology such as clinical or pre clinical Alzheimer's disease, Down's syndrome, or clinical or pre- clinical amyloid angiopathy, using standard administration techniques, preferably peripherally (i.e. not by administration into the central nervous system) by intravenous, intraperitoneal, subcutaneous, pulmonary, transdermal, intramuscular, intranasal, buccal, sublingual, or suppository administration. Although the antibodies may be administered directly into the ventricular system, spinal fluid, or brain parenchyma, and techniques for addressing these locations are well known in the art, it is not necessary to utilize these more difficult procedures. The antibodies of the invention are effective when administered by the more simple techniques that rely on the peripheral circulation system. The advantages of the present invention include the ability of the antibody exert its beneficial effects even though not provided directly to the central nervous system itself. Indeed, it has been demonstrated herein that the amount of antibody which crosses the blood-brain barrier is <0. 1 % of plasma levels and that the antibodies of the invention exert their ability to sequester A $\beta$  in the peripheral circulation as well as to alter CNS and plasma soluble A $\beta$  clearance.
- The pharmaceutical compositions for administration are designed to be appropriate for the selected mode of administration, and pharmaceutically acceptable excipients such as dispersing agents, buffers, surfactants, preservatives, solubilizing agents, isotonicity agents, stabilizing agents and the like are used as appropriate. Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton PA, latest edition, incorporated herein by reference, provides a compendium of formulation techniques as are generally known to practitioners.

- It may be particularly useful to alter the solubility characteristics of the antibodies of the invention, making them more lipophilic, for example, by encapsulating them in liposomes or by blocking polar groups.
- Peripheral systemic delivery by intravenous or intraperitoneal or subcutaneous injection is preferred. Suitable vehicles for such injections are straightforward. In addition, however, administration may also be effected through the mucosal membranes by



means of nasal aerosols or suppositories. Suitable formulations for such modes of administration are well known and typically include surfactants that facilitate cross-membrane transfer. Such surfactants are often derived from steroids or are cationic lipids, such as N-[1-(2,3-dioleoyl)propyl]-N,N,N-trimethylammoniumchloride(DOTMA) or various compounds such as cholesterol hemisuccinate, phosphatidyl glycerols and the like.

The concentration of the humanized antibody in formulations from as low as about 0.1 % to as much as 15 or 20% by weight and will be selected primarily based on fluid volumes, viscosities, and so forth, in accordance with the particular mode of administration selected. Thus, a typical pharmaceutical composition for injection could be made up to contain 1 mL sterile buffered water of phosphate buffered saline and 1-100 mg of the humanized antibody of the present invention. The formulation could be sterile filtered after making the formulation, or otherwise made microbiologically acceptable. A typical composition for intravenous infusion could have a volume as much as 250 mL of fluid, such as sterile Ringer's solution, and 1-100 mg per mL, or more in antibody concentration.

Therapeutic agents of the invention can be frozen or Lyophilized for storage and reconstituted in a suitable sterile carrier prior to use. Lyophilization and reconstitution can lead to varying degrees of antibody activity loss (e.g. with conventional immune globulins, IgM antibodies tend to have greater activity loss than IgG antibodies). Dosages may have to be adjusted to compensate. The pH of the formulation will be selected to balance antibody stability (chemical and physical) and comfort to the patient when administered.

Generally, pH between 4 and 8 is tolerated.

Although the foregoing methods appear the most convenient and most appropriate for administration of proteins such as humanized antibodies, by suitable adaptation, other techniques for administration, such as transdermal administration and oral administration may be employed provided proper formulation is designed.

In addition, it may be desirable to employ controlled release formulations using biodegradable films and matrices, or osmotic mini-pumps, or delivery systems based on dextran beads, alginate, or collagen.

In summary, formulations are available for administering the antibodies of the invention and are well-known in the art and may be chosen from a variety of options. Typical dosage levels can be optimized using standard clinical techniques and will be dependent on the mode of administration and the condition of the patient.

The present invention further provides kits that can be used in the above mentioned methods. In one embodiment, a kit comprises an antibody of the invention, preferably a purified antibody, more preferably a monoclonal antibody, even more preferably the isolated monoclonal antibodies expressed by the hybridoma cells J&JPRD/hA $\beta$ 11/1 and J&JPRD/hA $\beta$ 11/2 deposited at the Belgian coordinated collection of microorganisms on August 19, 2002 with accessionnumbers LMBP 5896CB and LMBP 5897CB respectively, in one or more containers. In a specific embodiment, the kits of the present invention contain a substantially isolated polypeptide comprising an epitope which is specifically immunoreactive with an antibody included in the kit. In a further embodiment this epitope is being selected from the group consisting of the first 5 to 7 human amino acids of the  $\beta$ -secretase<sub>11</sub> cleavage site, i.e. EVHHQ-C (human A $\beta$ <sub>11</sub>(6 AA) – Seq Id No.:1) and EVHHQKL-C (human A $\beta$ <sub>11</sub>(8 AA) – Seq Id No.:2) or of the first 5 to 7 mouse amino acids of the  $\beta$ -secretase<sub>11</sub> cleavage site, i.e. EVRHQ-C (mouse A $\beta$ <sub>11</sub>(6 AA) – Seq Id No.:3) and EVRHQKL-C (mouse A $\beta$ <sub>11</sub>(8 AA) – Seq Id No.:4) as immunogens. Preferably, the kits of the present invention are used in a sandwich assay and further comprise a coating antibody which does not specifically react with the polypeptide of interest, in a specific embodiment this coating antibody recognizes the A $\beta$ 11-x peptides and full length A $\beta$ 40 or A $\beta$ 42, preferably this coating antibody recognizes the human A $\beta$ 11-x peptides and full length human A $\beta$ 40 or A $\beta$ 42, in a more preferred embodiment the coating antibody consists of the monoclonal antibody JRF/cA $\beta$ 40/10 (as characterized hereinbefore) that specifically recognizes A $\beta$ 11-40 and full length A $\beta$ 40 or the coating antibody consists of the monoclonal antibody JRF/cA $\beta$ 42/12 (as characterized hereinbefore) that specifically recognizes A $\beta$ 11-42 and full length A $\beta$ 42. In alternative sandwich assay according to the invention, the kits will comprise a coating antibody that specifically recognizes the A $\beta$ 11-x peptides, preferably the human A $\beta$ 11-x peptides, and further antibodies specific for the C-terminus of A $\beta$ 40 or A $\beta$ 42, preferably for the C-terminus of human A $\beta$ 40 or A $\beta$ 42. In a more preferred embodiment the kit will comprise the isolated monoclonal antibodies expressed by the hybridoma cells J&JPRD/hA $\beta$ 11/1 and J&JPRD/hA $\beta$ 11/2 deposited at the Belgian coordinated collection of microorganisms on August 19, 2002 with accessionnumbers LMBP 5896CB and LMBP 5897CB respectively, as coating antibodies, and the monoclonal antibodies JRF/cA $\beta$ 40/10 (as characterized hereinbefore) and the monoclonal antibody JRF/cA $\beta$ 42/12 (as characterized hereinbefore) as further antibodies, the latter being conjugated to a detectable label, substrate.

In another specific embodiment, the kits of the present invention contain means for detecting the binding of an antibody to a polypeptide of interest (e.g., the antibody

may be conjugated to a detectable substrate such as a fluorescent compound, an enzymatic substrate, a radioactive compound or a luminescent compound, or a second antibody which recognizes the first antibody may be conjugated to a detectable substrate). In particular the kit contains means to detect the binding of an antibody to Ab11-x peptides, preferably to detect binding with an epitope being selected from the group consisting of the first 5 to 7 human amino acids of the  $\beta$ -secretase<sub>11</sub> cleavage site, i.e. EVHHQ-C (human A $\beta$ <sub>11</sub>(6 AA) – Seq Id No.:1) and EVHHQKI-C (human A $\beta$ <sub>11</sub>(8 AA) – Seq Id No.:2) or of the first 5 to 7 mouse amino acids of the  $\beta$ -secretase<sub>11</sub> cleavage site, i.e. EVRHQ-C (mouse A $\beta$ <sub>11</sub>(6 AA) – Seq Id No.:3) and EVRHQKL-C (mouse A $\beta$ <sub>11</sub>(8 AA) – Seq Id No.:4). In the aforementioned sandwich assays, the antibody conjugated to a detectable substrate will not be the coating antibody.

In an additional embodiment, the invention includes a diagnostic kit for use in screening biological samples including tissue, body fluids, such as CSF, blood, plasma, serum, urine, and the like. Said biological sample containing Ab11-x peptides. The diagnostic kit includes a substantially isolated antibody specifically immunoreactive with Ab11-x peptides, in particular with an epitope being selected from the group consisting of the first 5 to 7 human amino acids of the  $\beta$ -secretase<sub>11</sub> cleavage site, i.e. EVHHQ-C (human A $\beta$ <sub>11</sub>(6 AA) – Seq Id No.:1) and EVHHQKI-C (human A $\beta$ <sub>11</sub>(8 AA) – Seq Id No.:2) or of the first 5 to 7 mouse amino acids of the  $\beta$ -secretase<sub>11</sub> cleavage site, i.e. EVRHQ-C (mouse A $\beta$ <sub>11</sub>(6 AA) – Seq Id No.:3) and EVRHQKL-C (mouse A $\beta$ <sub>11</sub>(8 AA) – Seq Id No.:4), and means for detecting the binding of the antibody to the immunogen. In one embodiment, the antibody is attached to a solid support. In a specific embodiment, the antibody may be a monoclonal antibody, in particular the monoclonal antibodies expressed by the hybridoma cells J&JPRD/hA $\beta$ 11/1 and J&JPRD/hA $\beta$ 11/2 deposited at the Belgian coordinated collection of microorganisms on August 19, 2002 with accession numbers LMBP 5896CB and LMBP 5897CB respectively.

The detecting means of the kit may include a second, labeled monoclonal antibody, preferably this second labeled antibody consists of JRF/cA $\beta$ 40/10 or JRF/cA $\beta$ 42/12 wherein the combination of the aforementioned immobilized monoclonal antibodies with JRF/cA $\beta$ 40/10 specifically recognizes A $\beta$ 11-40 without cross reaction with A $\beta$ 1-40 and wherein the combination of the aforementioned immobilized monoclonal antibodies with JRF/cA $\beta$ 42/12 specifically recognizes A $\beta$ 11-42 without cross reaction with A $\beta$ 1-42. Alternatively, or in addition, the detecting means may include a labeled, competing antigen.

The solid surface reagent in the above assay is prepared by known techniques for attaching protein material to solid support material, such as polymeric beads, dip sticks, 96-well plate or filter material. These attachment methods generally include non-specific adsorption of the protein to the support or covalent attachment of the protein, typically through a free amine group, to a chemically reactive group on the solid support, such as an activated carboxyl, hydroxyl, or aldehyde group. Alternatively, streptavidin coated plates can be used in conjunction with biotinylated antigen(s).

Thus, the invention provides an assay system or kit for carrying out this diagnostic method. The kit generally includes a support with surface-bound antibodies according to the invention, and a reporter-labeled antibody for detecting the binding of the antibody to the immunogen.

This invention will be better understood by reference to the Experimental Details that follow, but those skilled in the art will readily appreciate that these are only illustrative of the invention as described more fully in the claims that follow thereafter. Additionally, throughout this application, various publications are cited. The disclosure of these publications is hereby incorporated by reference into this application to describe more fully the state of the art to which this invention pertains.

## EXPERIMENTAL

### MATERIAL AND METHODS

5

#### Generation of monoclonal antibodies

Balb/c mice were primed with four different peptides in complete Freund's adjuvant. The first two synthetic peptides comprised the first 5 to 7 human amino acids (AA) at the  $\beta$ -secretase<sub>11</sub> cleavage site: EVHHQ(KI)-C (human A $\beta$ <sub>11</sub> (6 or 8 AA)). The  
10 other two peptides for immunisation contained a mouse A $\beta$ <sub>11</sub> AA sequence; EVRHQ(KL)-C. All the peptides were prepared by coupling the peptides via a COOH-terminal cystein residue to maleimide activated mc(*Megathura crenulata*) KLH, or to Maleimide Activated Bovine Serum Albumin, using commercially available kits such as the Inject Maleimide Activated mcKLH/BSA kit of Pierce, according to the  
15 manufacturer's instructions (Pierce, Rockford, IL). Mice were boosted every two weeks with 100  $\mu$ g KLH-coupled peptide, first in Complete and subsequently in Incomplete Freund's adjuvant.

The spleens of all mice were isolated and frozen in liquid nitrogen except for one spleen of a mouse immunised with human A $\beta$ <sub>11</sub> (6AA) peptide. The mouse  
20 selected showed the highest serum titer and was therefore selected for fusion. On day 4 before fusion or spleen extraction, all mice were boosted intraperitoneally with 100  $\mu$ g of A $\beta$ <sub>11</sub> peptides coupled to mcKLH in saline. Mouse spleen cells were fused with SP2/0 cells by a modified procedure of Kohler and Milstein (8). The hybridoma's were seeded in 30 x 96-well plates and screened after 10 days in a direct ELISA on BSA-coupled hA $\beta$ <sub>11</sub> peptide of 6 AA and confirmed on non-coupled A $\beta$ <sub>11</sub>-40 peptide.  
25 Positive cells on free hA $\beta$ <sub>11</sub>-40 were immediately subcloned and positive clones were frozen in liquid nitrogen.

All hybridoma's were grown in Dulbecco's modified Eagle's medium supplemented with 10 % foetal calf serum (Hyclone, Europe), 2.5% ESG Hybridoma supplement (Elscolab, Kruike, Belgium), 2% HT (Sigma, USA), 1 mM sodium pyruvate, 2 mM L-glutamine and penicillin (100 U/ml) and Streptomycin (50 mg/ml).  
30 All products were commercially available and purchased from Life-Technologies (Paisley, U.K.). Cells were incubated in a humidified 8 % CO<sub>2</sub> air incubator.

#### ELISA Antibody selection

The screening ELISA used for the detection of anti-A $\beta$ <sub>11</sub> antibodies was a direct ELISA with 1  $\mu$ g/ml free human/mouse A $\beta$ <sub>11-40</sub> or BSA coupled human/mouse A $\beta$ <sub>11</sub> peptide coated overnight at 4 °C in NUNC (Life Technologies) U-bottom high-binding 96-well microtiter plates in 50  $\mu$ l/well coating buffer (10 mM Tris, 10 mM NaCl, and 10 mM NaN<sub>3</sub>, pH 8.5). The next day, the plates were coated with 85  $\mu$ l/well of 0.1 % casein in PBS for 60 min at 37 °C to reduce non-specific binding. Next, 50  $\mu$ l hybridoma supernatant was added and incubated for 1 h at 37 °C. After washing, the bound monoclonal antibodies were detected with 50  $\mu$ l/well of Sheep-anti-mouse Ig conjugated with horseradish peroxidase for 1 hr at 37 °C (Amersham-Pharmacia Biotech). Both reagents were diluted in 0.1 % Casein/PBS. The plates were washed and 50  $\mu$ l of a solution of 0.42 mM 3,5,3',5'-tetramethyl-benzidine, 0.003 % (vol/vol) H<sub>2</sub>O<sub>2</sub> in 100 mM citric acid and 100 mM disodium hydrogen phosphate (pH 4.3) was added as the substrate. The reaction was allowed to proceed for maximum 15 min on a plate shaker at room temperature, after which the colour development was stopped with 2 N H<sub>2</sub>SO<sub>4</sub>, 50  $\mu$ l/well and the plates, were read on a microtiter plate reader at 450 nm (Thermomax, Molecular Devices). The cross-reactivity of the selected monoclonal antibodies with full-size human free A $\beta$ <sub>1-40</sub> peptide was tested in a direct ELISA, identical to the screening assay, except that full-size free human A $\beta$ <sub>1-40</sub> peptide was used instead of BSA coupled hA $\beta$ <sub>11</sub> (6AA) peptide. In a second confirmation ELISA, the selected positive cultures were re-tested on free human A $\beta$ <sub>11-40</sub> peptide.

#### Sandwich ELISA for amyloid $\beta$ detection

The ELISA for the measurement of hA $\beta$ (1-40) or hA $\beta$ (11-40) standard dilutions (American Peptide Company) was performed as follows: Briefly, monoclonal antibodies JRF/A $\beta$ N/25, J&JPRD/hA $\beta$ 11/1 and J&JPRD/hA $\beta$ 11/2 were coated at 5  $\mu$ g/ml overnight at 4 °C in NUNC flat-bottom high-binding 96-well microtiter plates in 100  $\mu$ l/well coating buffer. The next day, plates were overcoated with 125  $\mu$ l/well of 0.1 % casein in PBS for 30 min at 37 °C to reduce non-specific binding and incubated with 100  $\mu$ l/well of hA $\beta$ (1-40) or hA $\beta$ (11-40) peptide dilution samples for 90 min at 37 °C. The plates were washed followed by an incubation with 100  $\mu$ l/well of HRP-labeled JRF/cA $\beta$ 40/10-HRPO. The plates were washed and 100  $\mu$ l of a solution of 0.42 mM 3,5,3',5'-tetramethyl-benzidine, 0.003 % (vol/vol) H<sub>2</sub>O<sub>2</sub> in 100 mM citric acid and 100 mM disodium hydrogen phosphate (pH 4.3) was added as the substrate. The reaction was allowed to proceed for maximum 15 min on a plate shaker at RT, after which the

color development was stopped with 2 N H<sub>2</sub>SO<sub>4</sub>, 50 µl/well and the plates were read on a microtiter plate reader at 450 nm (Thermomax, Molecular Dynamics).

5 Immunodetection of APP CTF.

For immunodetection of CTF (STUBS) fragments, HEK cells, stably transfected with Human APP<sup>swe</sup> and Human BACE1, were grown in 75 cm<sup>2</sup> flasks (Life Technologies, Paisly, UK) until confluence and cells were subsequently lysed and sonicated in 50 mM Tris: pH=7.0, 0.15 M NaCl, 1% Triton X-100 and a commercially available Protease-Inhibitor-Cocktail (Roche, Boehringer Mannheim, Germany). Crude lysates were centrifuged at 10 000 g at 4 °C for 10 min to remove nuclei and debris. Cleared cell lysates were normalized for protein content and samples were denatured at 95 °C in 2x Tricine Laemmli buffer for 5 min and loaded onto precast 10-20% Tris Tricine SDS gradient gels (NOVEX, Invitrogen, Groningen, The Netherlands) and semi-dry blotted to 0.22 µm Hybond-ECL nylon membranes (APB) for 45 min at 1.5 mA per cm<sup>2</sup>. A low molecular weight protein ladder was used as molecular weight standard (MagicMark Western standard, Invitrogen). The membranes were blocked with 10 % (w/v) non-fat dry milk (BioRad) in PBS for 1 hour. Next they were incubated with the appropriate monoclonal antibody at 5 µg/ml overnight at 4 °C (monoclonal antibody C1/6.1 directed against a C-terminal epitope in APP, was a generous gift of Dr. Mathews, Nathan S. Kline Institute, Orangeburg). The membranes were then washed in PBS-0.1 % Tween20 for 5 min with five changes of buffer, incubated for 1 h with a HRP-conjugated goat anti-mouse (Sigma) 1:2000 dilution for 1 h at room temperature (RT). After washing, the bands of interest were visualised by chemiluminescence according to the manufacturer's instructions (Roche, Boehringer Mannheim, Germany). Scans were taken with a Lumi-Imager (Roche, Boehringer Mannheim, Germany).

## RESULTS AND DISCUSSION

### Selection of the "fusion mouse"

- 5 A panel of 4 different mKLH coupled peptides was injected in mice. For each peptide, 3 different mice were immunized. After the first boost immunisation, each mouse was bled and serum was isolated and tested in directly coated BSA-humanA $\beta$  (6AA) ELISA's. The immunisation protocol of mice immunised with hA $\beta$ \_11 (6AA) was identical for all mice injected and is shown in table 1. In figure 1.a, it is clearly  
10 demonstrated that mouse 1 immunised with KLH\_hA $\beta$ \_11 (6AA) (SEQ ID No:1) shows a very high serum titer for free human A $\beta$ 11-40 peptide. For this reason, mouse 1 immunised with hA $\beta$ \_11 (6AA) was selected for fusion

### Fusion of hA $\beta$ \_11 (6aa), spleen 1

- 15 Due to the large number of spleen cells of this hyper immunised mouse (a total of  $6.5 \times 10^8$  spleen cells), the fusion procedure was performed twice with half of the spleen cell number. All cells were seeded in medium supplemented with ESG and 30 x 96 hybridoma plates were screened after 10 days.  
Out of these hybridomas, 65 culture wells initially showed a clear positive signal in the  
20 screening ELISA assay on BSA-coupled peptide. All these positive supernatant were tested on free peptide in an IgG specific ELISA. Only 5 cultures were confirmed positive or less than 10% of the initial positive wells. All these cultures were negative on full-length human A $\beta$ 1-40, indicating reactivity to the end-standing AA of hA $\beta$ 11-40/42.  
25 The cultures were immediately cloned and the mother cultures were frozen. Out of these 5, 2 hybridoma's named 29B5 (J&JPRD/hA $\beta$ 11/1) and 5C4 (J&JPRD/hA $\beta$ 11/2) were successfully cloned and frozen in liquid Nitrogen. Of these two hybridoma's 4 different subclones each were cultured and frozen. In table 2, the positive subclones are summarised.

30

### Conclusion

Out of a total of more than 30.000 hybridomas, we selected two different hybridoma clones that recognise specifically the free N-terminus of the human A $\beta$ 11-40 peptide. These monoclonal antibodies are negative on full size human A $\beta$ 1-40.



To evaluate the specificity of the antibodies, they were purified on Protein G affinity chromatography and used in a sandwich ELISA with specific anti-human cA $\beta$ 40 and cA $\beta$ 42 mAbs. JRF/A $\beta$ N/25 was used as a specific monoclonal antibody for A $\beta$ 1-40 in combination with JRF/cA $\beta$ 40/10-HRPO as detecting antibody. The latter specifically  
5 recognizes the C-terminal part of A $\beta$  and can accordingly be used as detecting antibody both with JRF/A $\beta$ N/25 and J&JPRD/hA $\beta$ 11/1 and J&JPRD/hA $\beta$ 11/2 the antibodies specific for the A $\beta$ 11-x peptides. Figure 2A confirms that JRF/A $\beta$ N/25 specifically reacts with A $\beta$ 1-40 without crossreactivity to A $\beta$ 11-40. From Figures 2B and 2C it can  
10 be seen that the antibodies J&JPRD/hA $\beta$ 11/1 and J&JPRD/hA $\beta$ 11/2 specifically recognize hA $\beta$ 11-40 without cross reaction to human A $\beta$ 1-40.

The capability of the antibodies according to the invention to specifically label the A $\beta$ 11-x peptides in a biological sample was demonstrated in a Western blot on a membrane extract of HEK cells stably transfected with human APP and human BACE1  
15 (Fig.3). Accordingly, the use of these antibodies in combination with specific anti-human cA $\beta$ 40 and anti-human cA $\beta$ 42 monoclonal antibodies in sandwich ELISA's, might yield sensitive assays to detect specifically human A $\beta$ 11-x peptides in different biological samples, including biological fluids and brain homogenates.

References

1. Jarrett, J.T., Berger, E.P., Lansbury, P.T., The carboxy terminus of the beta amyloid  
5 protein is critical for the seeding of amyloid formation: implications for the  
pathogenesis of Alzheimer's disease. *Biochem.* 32 (1993) 4693-4697.
2. Selkoe, DJ., Alzheimer's disease: genes, proteins, and therapy. *Physiol. Rev.* 81  
(2001):741-766
3. Gouras, G.K., Xu, H., Jovanovic, J.N., Buxbaum, J.D., Wang, R., Relkin, N.R.,  
10 Gandy, S., Generation and regulation of beta-amyloid peptide variants by neurons, *J.*  
*Neurochem.*, 71 (1998) 1920-1925.
4. Wang, R., Sweeney, D., Gandy, S.E., Sisodia, S.S., The profile of soluble amyloid  
beta protein in cultured cell media. Detection and quantification of amyloid beta protein  
and variants by immunoprecipitation-mass spectrometry, *J. Biol. Chem.*, 271 (1996)  
15 31894-31902.
5. Vandermeeren, M., Geraerts, M., Pype, S., Dillen, L., Van Hove, C., Mercken, M.,  
The functional inhibitor DAPT prevents production of amyloid  $\beta$  1-34 in human and  
murine cell lines. *Neurosci. Lett.* 315 (2001) 145-148.
6. Naslund, J., Schierhorn, A., Hellman, U., Lannfelt, L., Roses A.D, Tjernberg, L.O.,  
20 Silberring, J., Gandy, S.E., Winblad, B., Greengard, P., Nordstedt, C., Terenius, L.,  
Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease  
and normal aging, *Proc. Natl. Acad. Sci. U. S. A.*, 91 (1994) 8378-8382.
7. Iwatsubo, T., Saido, T.C., Mann D.M., Lee, V.M.-Y., Trojanowski, J.Q. Full-length  
amyloid-beta (1-42(43)) and amino-terminally modified and truncated amyloid-beta  
25 42(43) deposit in diffuse plaques. *Am. J. Pathol.* 149 (1996) 1823-1830.
8. Kohler, G., Howe, S.C., Milstein, C., Fusion between immunoglobulin-secreting and  
nonsecreting myeloma cell lines. *Eur J Immunol* 6 (1976) 292-295

-24-  
SEQUENCE LISTING

5   <110>   Janssen Pharmaceutica N.V.

10   <120>   Amyloid-Beta monoclonal antibodies, compositions, methods and  
uses

15   <130>   PRD 32

20   <160>   10

25   <170>   PatentIn version 3.1

30   <210>   1  
      <211>   5  
      <212>   PRT  
      <213>   Artificial Sequence

35   <220>

40   <223>   Immunogen consisting of the first 5 amino acids of the BACE1  
          cleavage site of human amyloid beta

45   <400>   1  
          Glu Val His His Gln  
          1                   5

50   <210>   2  
      <211>   7  
      <212>   PRT  
      <213>   Artificial Sequence

55   <220>

60   <223>   Immunogen consisting of the first 7 amino acids of the BACE1  
          cleavage site of human amyloid beta

      <400>   2  
          Glu Val His His Gln Lys Ile

1		5
5	<210>	3
	<211>	5
	<212>	PRT
10	<213>	Artificial Sequence
15	<220>	
	<223>	Immunogen consisting of the first 5 amino acids of the BACE1 cleavage site of mouse amyloid beta
20	<400>	3
	Glu Val Arg His Gln	
	1	5
25	<210>	4
	<211>	7
	<212>	PRT
30	<213>	Artificial Sequence
35	<220>	
	<223>	Immunogen consisting of the first 7 amino acids of the BACE1 cleavage site of mouse amyloid beta
40	<400>	4
	Glu Val Arg His Gln Lys Leu	
	1	5
45	<210>	5
	<211>	136
50	<212>	PRT
	<213>	Mus sp.
55	<220>	
	<221>	CDR1
60	<222>	(50) .. (54)
	<223>	

<220>  
5 <221> CDR2  
<222> (69)..(85)  
10 <223>  
  
<220>  
15 <221> CDR3  
<222> (118)..(125)  
20 <223>  
  
<400> 5  
25 Met Lys Cys Ser Trp Val Ile Phe Phe Leu Met Ala Val Val Ile Gly  
1 5 10 15  
30 Ile Asn Ser Glu Gly Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg  
20 25 30  
35 Ser Gly Ala Ser Leu Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile  
35 40 45  
40 Lys Asp His Tyr Val His Trp Val Arg Gln Arg Pro Glu Gln Gly Leu  
50 55 60  
45 Asp Trp Ile Gly Trp Ile Ala Pro Lys Asn Gly Tyr Ser Glu Ser Ala  
65 70 75 80  
50 Pro Lys Phe Gln Gly Lys Ala Ser Met Thr Ala Asp Thr Ser Ser Asn  
85 90 95  
55 Thr Val Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val  
100 105 110  
60 Tyr Tyr Cys Phe Ala Gly Phe Tyr Asp Ser Ser Leu Tyr Trp Gly Gln  
115 120 125  
65 Gly Thr Thr Leu Thr Val Ser Ser  
130 135  
60  
<210> 6  
<211> 133

<212> PRT  
 <213> Mus sp.

5

<220>

10 <221> CDR1  
 <222> (44)..(59)  
 <223>

15

<220>

20 <221> CDR2  
 <222> (75)..(81)  
 <223>

25

<220>

30 <221> CDR3  
 <222> (114)..(122)  
 <223>

35

<400> 6

40 Met Met Ser Pro Ala Gln Phe Leu Phe Leu Leu Val Leu Trp Ile Arg  
 1 5 10 15

Glu Thr Asn Gly Asp Val Val Met Thr Gln Thr Pro Leu Thr Leu Ala  
 20 25 30

45 Val Thr Ile Gly Gln Pro Ala Ser Ile Ser Cys Lys Ser Gly Gln Ser  
 35 40 45

50 Leu Leu Ala Arg Asp Gly Lys Thr Tyr Leu Ser Trp Leu Leu Gln Arg  
 50 55 60

55 Pro Gly Gln Ser Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp  
 65 70 75 80

60 Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe  
 85 90 95

Thr Leu Lys Ile Asn Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr  
 100 105 110

Cys Trp Gln Gly Thr His Phe Pro Arg Thr Phe Gly Gly Gly Thr Asn  
 115 120 125  
 5  
 Leu Glu Ile Lys Arg  
 130  
 10  
 <210> 7  
 <211> 133  
 15  
 <212> PRT  
 <213> Mus sp.  
 20  
 <220>  
 <221> CDR1  
 25  
 <222> (50)..(54)  
 <223>  
 30  
 <220>  
 <221> CDR2  
 35  
 <222> (69)..(85)  
 <223>  
 40  
 <220>  
 <221> CDR3  
 45  
 <222> (118)..(122)  
 <223>  
 50  
 <400> 7  
 Met Gly Trp Ser Trp Ile Phe Leu Phe Leu Leu Ser Gly Thr Ala Gly  
 1 5 10 15  
 55  
 Val Leu Ser Glu Val Gln Leu Gln Gln Ser Gly Pro Asp Leu Val Lys  
 20 25 30  
 60  
 Pro Gly Ala Ser Val Lys Thr Ser Cys Lys Thr Ser Gly Tyr Ser Phe  
 35 40 45



5

10

15

20

25

**<211> 133**

30

**<220>**

~~222~~ (44) .. (59)

45

**<221> CDR2**

50

**<220>**

 $\langle 222 \rangle \quad (114) \dots (122)$ 

<223>



<400> 8

5 Met Arg Phe Ser Ala Gln Leu Leu Gly Leu Leu Val Leu Trp Ile Pro  
1 5 10 15

10 Gly Ser Thr Ala Asp Ile Val Met Thr Gln Ala Ala Phe Ser Asn Pro  
20 25 30

15 Val Thr Leu Gly Thr Ser Ala Ser Ile Ser Cys Arg Ser Ser Lys Asn  
35 40 45

20 Leu Leu His Ser Asn Gly Ile Thr Tyr Leu Tyr Trp Tyr Leu Gln Arg  
50 55 60

25 Pro Gly Gln Ser Pro Gln Leu Leu Ile Ser Arg Val Ser Asn Leu Ala  
65 70 75 80

30 Ser Gly Val Pro Asn Arg Phe Ser Gly Ser Glu Ser Gly Thr Asp Phe  
85 90 95

35 Thr Leu Arg Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr  
100 105 110

40 Cys Ala Gln Leu Leu Glu Leu Pro Phe Thr Phe Gly Ser Gly Thr Lys  
115 120 125

45 Leu Glu Ile Lys Arg  
130

<210> 9

40 <211> 138

<212> PRT

45 <213> Mus sp.

<220>

50 <221> CDR1

<222> (50) .. (54)

55 <223>

<220>

60 <221> CDR2

<222> (69) .. (85)

<223>

5 <220>

<221> CDR3

10 <222> (118)..(127)

<223>

15 <400> 9

Met Glu Trp Thr Trp Val Phe Leu Phe Leu Leu Ser Val Thr Ala Gly  
1 5 10 15

20 Val His Ser Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Met Lys  
20 25 30

25 Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Thr Gly Tyr Thr Phe  
35 40 45

30 Ser Thr Ser Trp Ile Glu Trp Ile Lys Gln Arg Pro Gly His Gly Leu  
50 55 60

35 Glu Trp Ile Gly Glu Val Leu Pro Gly Ser Gly Lys Ser Asn His Asn  
65 70 75 80

Ala Asn Phe Lys Gly Arg Ala Thr Phe Thr Ala Asp Thr Ala Ser Asn  
85 90 95

40 Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val  
100 105 110

45 Tyr Tyr Cys Ala Arg Glu Gly Ser Asn Asn Asn Ala Leu Ala Tyr Trp  
115 120 125

50 Gly Gln Gly Thr Leu Val Thr Val Ser Ala  
130 135

<210> 10

55 <211> 128

<212> PRT

60 <213> Mus sp.

<220>

<221> CDR1  
 <222> (46) .. (55)  
 5 <223>  
  
 10 <220>  
 <221> CDR2  
 <222> (60) .. (67)  
 15 <223>  
  
 20 <220>  
 <221> CDR3  
 <222> (110) .. (117)  
 25 <223>  
  
 30 <400> 10  
 Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser  
 1 5 10 15  
 35 Val Ile Ile Ser Arg Gly Gln Ile Val Leu Thr Gln Ser Pro Ala Ile  
 20 25 30  
 40 Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Ser Ala Ser  
 35 40 45  
 45 Ser Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys Ser Gly Thr Ser  
 50 55 60  
 Pro Lys Arg Trp Ile Tyr Asp Ser Ser Arg Leu Ala Ser Gly Val Pro  
 65 70 75 80  
 50 Ser Arg Phe Ser Gly Gly Gly Ser Gly Thr Ser Tyr Ser Pro Thr Ile  
 85 90 95  
 55 Ser Asn Met Glu Ala Glu Asp Ala Ala Thr Tyr Phe Cys Gln Asn Trp  
 100 105 110  
 60 Arg Ser Ser Pro Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg  
 115 120 125

WHAT IS CLAIMED IS:

1. The hybridoma cells J&JPRD/hA $\beta$ 11/1 and J&JPRD/hA $\beta$ 11/2 deposited at the Belgian coordinated collection of microorganisms on August 19, 2002 with accessionnumbers LMBP 5896CB and LMBP 5897CB respectively.
- 5 2. An antibody expressed by the hybridoma cells J&JPRD/hA $\beta$ 11/1 and J&JPRD/hA $\beta$ 11/2 deposited at the Belgian coordinated collection of microorganisms on August 19, 2002 with accessionnumbers LMBP 5896CB and LMBP 5897CB respectively, said antibodies capable of specifically  
10 recognizing A $\beta$ 11-x peptides.
3. An antibody as claimed in claim 2 that is detectably labeled.
4. An antibody as claimed in claim 3 wherein the detectable label is a radiolabel,  
15 an enzyme label, a luminescent label or a fluorescent label.
5. An antibody as claimed in claim 2 that is immobilized on a carrier.
6. An immunoassay method for the determination or detection of A $\beta$ 11-x peptides  
20 in a sample, the method comprising contacting the sample with an antibody to A $\beta$ 11-x peptides as claimed in claim 2 and determining whether an immune complex is formed between the antibody and the A $\beta$ 11-x peptide.
7. A method for the detection of the presence of A $\beta$ 11-x peptides in a tissue  
25 sample, the method comprising:  
obtaining a tissue sample from the body of a subject;  
contacting the tissue sample with an imaging effective amount of a detectably labeled antibody as claimed in claim 3 or 4; and

detecting the label to establish the presence of A $\beta$ 11-x peptides in the tissue sample.

- 5      8.      A method for the detection of the presence of A $\beta$ 11-x peptides in a body fluid sample, the method comprising:
- obtaining a body fluid sample from the body of a subject;
- contacting the body fluid sample with an imaging effective amount of a detectably labeled antibody as claimed in claim 3 or 4; and
- 10      detecting the label to establish the presence of A $\beta$ 11-x peptides in the body fluid sample.
9.      The use of an antibody as claimed in any of claims 2 to 5 for the diagnosis of  $\beta$ -amyloid-related diseases.
- 15      10.      A diagnostic composition comprising an antibody as claimed in any of claims 2 to 5 and a pharmaceutically acceptable carrier.
- 20      11.      An immunoassay kit for the diagnosis of  $\beta$ -amyloid-related diseases comprising an antibody as claimed in any of claims 2 to 5 and carrier means for the antibody.

## ABSTRACT

5

**AMYLOID-BETA MONOCLONAL ANTIBODIES, COMPOSITIONS,  
METHODS AND USES**


---

10

This invention relates to antibodies, including specified portions or variants, specific for at least the human Amyloid-beta<sub>11</sub> N-terminal site, *i.e.* A $\beta$ <sub>11-x</sub> peptides. It further provides methods of making and using said antibodies, including therapeutic formulations, administration and devices.

15

Fig.1.A.



**Table 1.**

Immunisation/bleeding	Date	Mouse	Injected	
Priming	23/01/2002	1	100 µg	
	23/01/2002	2	100 µg	
	23/01/2002	3	100 µg	
Boost 1	06/02/2002	1	100 µg	
	06/02/2002	2	100 µg	
	06/02/2002	3	100 µg	
Bleeding 1	20/02/2002	1		
	20/02/2002	2		
	20/02/2002	3		
Boost 2	27/02/2002	1	100 µg	
	27/02/2002	2	100 µg	
	27/02/2002	3	100 µg	
Bleeding 2	08/03/2002	1		
	08/03/2002	2		
	08/03/2002	3		
Final boost	11/03/2002	1	100 µg	Mouse with ascites !
	11/03/2002	2	100 µg	Mouse with ascites !
	11/03/2002	3	100 µg	No ascites , no titer !
Spleen frozen	Mouse	DATE		Spleen Cells
hAβ 11(6aa).10exp6 cellen	2	14/03/2002		105.10exp6/vial (4 vials)
FUSION	Mouse	DATE		Spleen Cells
hAβ 11(6aa) 30pl.	1	15/03/2002		655.10exp6
				2 fusions with each $925 \times 10^6$ spleen cells



Fig2A




Fig2B




Fig2C




Fig 3

**J&JPRD/hAβ11/1 C1/6.1**

**β11 stub**



**β1 stub  
β11 stub**

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☒ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☒ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**